Abstract

Olfaction plays an important role in mammalian social behavior. Olfactory deficits are common in schizophrenia and correlate with negative symptoms and low social drive. Despite their prominence and possible clinical relevance, little is understood about the pathological mechanisms underlying olfactory deficits in schizophrenia and there are currently no effective treatments for these deficits. The prosocial neuropeptide oxytocin may affect the olfactory system when administered intranasally to humans and there is growing interest in its therapeutic potential in schizophrenia. To examine this model, we administered 40IU of oxytocin and placebo intranasally to 31 patients with a schizophrenia spectrum illness and 34 age-matched healthy control participants in a randomized, double-blind, placebo-controlled, cross-over study. On each test day, participants completed an olfactory detection threshold test for two different odors: (1) lyral, a synthetic fragrance compound for which patients with schizophrenia have specific olfactory detection threshold deficits, possibly related to decreased cyclic adenosine 3',5'-monophosphate (cAMP) signaling; and (2) anise, a compound for which olfactory detection thresholds change with menstrual cycle phase in women. On the placebo test day, patients with schizophrenia did not significantly differ from healthy controls in detection of either odor. We found that oxytocin administration significantly and selectively improved olfactory detection thresholds for lyral but not for anise in patients with schizophrenia. In contrast, oxytocin had no effect on detection of either odor in healthy controls. Our data indicate that oxytocin administration may ameliorate olfactory deficits in schizophrenia and suggest the effects of intranasal oxytocin may extend to influencing the olfactory system. Given that oxytocin has been found to increase cAMP signaling in vitro a possible mechanism for these effects is discussed.

Highlights

  • Patients with schizophrenia have significant olfactory impairments including difficulties with odor identification, detection threshold sensitivity, discrimination, and memory (Moberg et al, 2014)

  • Our data indicate that oxytocin administration may ameliorate olfactory deficits in schizophrenia and suggest the effects of intranasal oxytocin may extend to influencing the olfactory system

  • Olfaction plays a critical role in social behavior, such as emotion contagion, bonding, and mate selection in mammals, including humans (Stevenson, 2010); and deficits in odor identification correlate with negative symptoms in schizophrenia, in particular with low social drive (Malaspina and Coleman, 2003)

Read more

Summary

Introduction

Patients with schizophrenia have significant olfactory impairments including difficulties with odor identification, detection threshold sensitivity, discrimination, and memory (Moberg et al, 2014) These deficits are associated with smaller olfactory bulbs, worsen over the course of the illness, and are present in unaffected family members (Moberg et al, 2014). Olfaction plays a critical role in social behavior, such as emotion contagion, bonding, and mate selection in mammals, including humans (Stevenson, 2010); and deficits in odor identification correlate with negative symptoms in schizophrenia, in particular with low social drive (Malaspina and Coleman, 2003). More research needs to be conducted to elucidate the role of odor detection deficits in schizophrenia

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call